Jazz Pharmaceuticals plc Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Jazz Pharmaceuticals plc (JAZZ) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $167.80 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-02-24
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $167.80, a 12.63% increase from fiscal 2024.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $148.99, a 3.20% decline from fiscal 2023.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $153.92, a 1.98% decline from fiscal 2022.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $157.03, a 4.51% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $167.80 10-K · filed 2026-02-24 |
| 2024-12-31 | $148.99 10-K · filed 2025-02-26 |
| 2023-12-31 | $153.92 10-K · filed 2024-02-28 |
| 2022-12-31 | $157.03 10-K · filed 2023-03-01 |
| 2021-12-31 | $164.45 10-K · filed 2022-03-01 |
| 2020-12-31 | $159.41 10-K · filed 2021-02-23 |
| 2019-12-31 | $159.59 10-K · filed 2020-02-25 |
| 2018-12-31 | $169.18 10-K · filed 2019-02-26 |
| 2017-12-31 | $165.49 10-K · filed 2018-02-27 |
| 2016-12-31 | $167.31 10-K · filed 2017-02-28 |
| 2015-12-31 | $0.00 10-K · filed 2016-02-23 |
| 2014-12-31 | $0.00 10-K · filed 2015-02-24 |
| 2013-12-31 | $0.00 10-K · filed 2014-02-25 |
| 2012-12-31 | $0.00 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |